Archiv anzeigen:

Which Anthracycline for AML Induction Therapy?

Michael E. Williams, MD, ScM reviewing Lee JH et al. J Clin Oncol 2017 Aug 20

Daunorubicin and idarubicin provided similar benefits when combined with cytarabine for most patients with acute myeloid leukemia.

ACOG Updates Guidelines for Management of Hereditary Breast and Ovarian Cancer Syndrome

Andrew M. Kaunitz, MD reviewing American College of Obstetricians and Gynecologists. Obstet Gynecol 2017 Sep

Obstetrician-gynecologists play key roles, but should consider referral to a genetic specialist as necessary.

Prothrombin Complex Concentrate for Bleeding from Direct Oral Anticoagulants

David Green, MD, PhD reviewing Majeed A et al. Blood 2017 Aug 23

Treatment was effective for 70% of hemorrhages associated with apixaban or rivaroxaban.

From the Blogs: How to Land Your Dream PA or NP Job While You're Still in School

Physician assistant and clinical preceptor in gynecologic oncology Megan Tetlow has some dos and don'ts for PA and NP students on rotations, in the In Practice blog.

Lung Cancer Rates Are Increasing Among Never-Smokers

Anne S. Tsao, MD reviewing Pelosof L et al. J Natl Cancer Inst 2017 Jul

From 1990 through 2013, the percentage of patients with non–small-cell lung cancer who never smoked rose from 8.0% to 14.9%.

Neoadjuvant CDK4/6 Inhibition for ER-Positive Breast Cancer

William J. Gradishar, MD reviewing Ma CX et al. Clin Cancer Res 2017 Aug 1

Palbociclib demonstrated activity in early-stage disease resistant to endocrine therapy, but prolonged exposure may be required.

Ruxolitinib for Essential Thrombocythemia Resistant to Hydroxyurea

David Green, MD, PhD reviewing Harrison CN et al. Blood 2017 Aug 9

Symptom relief was more rapid with ruxolitinib versus best available therapy, but adverse effects were more frequent.

Obinutuzumab vs. Rituximab for Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Vitolo U et al. J Clin Oncol 2017 Aug 10

Substituting obinutuzumab for rituximab during induction chemotherapy did not improve outcomes.

How Common Is Arterial Thromboembolism in Patients with Newly Diagnosed Cancer?

Joel M. Gore, MD reviewing Navi BB et al. J Am Coll Cardiol 2017 Aug 22, Yeh ETH and Chang HM. J Am Coll Cardiol 2017 Aug 22

Patients show an elevated risk for myocardial infarction and ischemic stroke 6 months after cancer diagnosis.

Decitabine vs. Azacitidine for Myelodysplastic Syndrome

David Green, MD, PhD reviewing Jabbour E et al. Blood 2017 Aug 3

Response rates were higher with decitabine, especially in higher-risk patients.

Seite von 59
Editorial Member Board Empfehlungen

Prof. Dr. med. Florian Otto

Tumor- und Brustzentrum ZeTuP, St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.

Kommentar weiterlesen

Pembrolizumab for Advanced Melanoma

Jeffrey A. Sosman, MD reviewing Ribas A et al. JAMA 2016 Apr 19, Bhatia S and Thompson JA. JAMA 2016 Apr 19

The objective response rate was 33%, and the median duration of response was 28 months.

PD-1 Blockade for Advanced Merkel-Cell Carcinoma

Jeffrey A. Sosman, MD reviewing Nghiem PT et al. N Engl J Med 2016 Apr 19

Pembrolizumab induced frequent and durable responses with manageable toxicity.

Platelet Transfusion for Intracerebral Hemorrhage Associated with Antiplatelet Therapy

Jaime Toro, MD reviewing Baharoglu MI et al. Lancet 2016 May 10

In a randomized trial, platelet transfusion was associated with worse outcomes in patients with spontaneous ICH who were on antiplatelet therapy.

Pembrolizumab Has Promising Activity in PD-L1–Positive Gastric Cancer

David H. Ilson, MD, PhD reviewing Muro K et al. Lancet Oncol 2016 May 3

Duration of response justifies further study.

Upfront Chemotherapy with Radiation Beneficial for Low-Grade Glioma

Santosh Kesari, MD, PhD, Jethro Hu, MD reviewing Buckner JC et al. N Engl J Med 2016 Apr 7

Long-term randomized-trial results show a dramatic improvement in survival for patients with low-grade glioma treated initially with radiation plus chemotherapy versus radiation alone.

Oral Triplet Therapy for Relapsed or Refractory Myeloma

Michael E. Williams, MD, ScM reviewing Moreau P et al. N Engl J Med 2016 Apr 28

Adding the oral proteasome inhibitor ixazomib to lenalidomide plus dexamethasone improved outcomes, even in high-risk subgroups.

Radiotherapy Does Not Improve Outcome in Locally Advanced Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Hammel P et al. JAMA 2016 May 3

Survival was similar with chemoradiotherapy or chemotherapy alone in patients without progression after induction chemotherapy.

Cardiac Toxicity Among Breast Cancer Patients in Routine Practice

William J. Gradishar, MD reviewing Thavendiranathan P et al. J Clin Oncol 2016 Apr 18

Patients had a threefold higher cumulative incidence of major cardiac events than did a control population without cancer.

Long-Term Outcomes in Hodgkin Lymphoma: The Impact of Initial Therapy

Michael E. Williams, MD, ScM reviewing Merli F et al. J Clin Oncol 2016 Apr 10, Engert A. J Clin Oncol 2016 Apr 10

Ten-year survival was similar with ABVD or BEACOPP, but BEACOPP was associated with a high rate of late second malignancies.

Gefitinib vs. Erlotinib for Previously Treated Advanced Lung Adenocarcinoma

Anne S. Tsao, MD reviewing Urata Y et al. J Clin Oncol 2016 Mar 28

The trial did not meet its primary endpoint of noninferiority for gefitinib in terms of progression-free survival.